Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2922 + TAS-102 ± Bevacizumab in Advanced Colorectal Cancer
NCT07044908Phase 2Recruiting
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
- Start
- Jul 2025
- Primary completion
- Jul 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of tqb2922 in colorectal cancer (CRC), sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical. Started Jul 2025; status: recruiting.
02
Drugs
tqb2922
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07044908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07044908.